SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is gaining significant attention as it ramps up production of key minerals like samarium and terbium, strengthening its position as a critical non-Chinese supplier for defense and high-tech sectors. Investors are closely monitoring the company's expansion into heavy rare earths and its strategic supply agreements, which are being bolstered by broader government initiatives to secure Western supply chains.

Tria is a self-custodial neobank and cross-chain payments infrastructure designed to make onchain money usable in everyday life. It combines card spending, trading, and earning in a single account experience, so users can move value across chains without manually bridging assets, switching networks, or managing chain-specific steps. Under the hood, Tria routes every action through BestPath, an ultra-fast routing and execution layer that takes an intent like “spend,” “swap,” “send,” or “earn” and completes it end-to-end on the optimal path. Tria operates in two modes: a consumer app that includes a Visa-powered card, spot swaps, perpetual futures, and Earn vaults, and a developer and institutional layer that integrates with protocols and ecosystems to embed Tria’s execution rails wherever value already moves. The end goal is simple: one continuous flow for money across chains, with self-custody by default and a product experience that feels effortless for normal users worldwide.

TRIA

TRIA is gaining momentum as investors anticipate a major upcoming partnership with a national online bank and further exchange listings. The community is actively discussing the platform's self-custodial neobanking features and strong transaction volume, though some participants remain cautious and debate the asset's long-term viability.

Silvaco Group, Inc. provides technology computer aided design software, electronic data automation software and semiconductor intellectual property. The TCAD, EDA and SIP solutions enable semiconductor and photonics companies to increase productivity, accelerate their product's time to market and reduce their development and manufacturing costs. Its services include SPICE Modeling Services, TCAD Modeling Services, Library Design Services and Library Characterization Services. The company was founded on November 18, 2009 and is headquartered in Santa Clara, CA.

Silvaco Group Inc.

Silvaco Group is currently attracting significant attention due to a combination of high trading volume and active speculation regarding its growth potential within the semiconductor software sector. Investors are closely monitoring the stock for a potential breakout as the community debates the impact of recent insider buying, analyst price target adjustments, and the integration of strategic acquisitions.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme market volatility and significant retail attention following its recent IPO, with investors debating whether the company's battle-tested drone autonomy software justifies its current valuation. The stock is a focal point of intense discussion due to its low float, heavy momentum, and speculative potential for future defense contracts, drawing comparisons to past high-hype market runners.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is trending as investors debate its valuation and growth prospects, with community discussion heavily focused on institutional insider buying and the impact of its AI-focused data licensing strategy. While some users are optimistic about the platform's long-term potential as an AI infrastructure asset, others remain skeptical, citing concerns over bot activity and heavy selling pressure from institutional participants.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the stock's role as a major exporter of U.S. LNG amid escalating geopolitical instability in the Middle East and the closure of key regional energy facilities. Community members are actively debating the potential for a significant squeeze as supply constraints tighten, while monitoring how the company's uncontracted spot market capacity positions it to capture windfall profits during the ongoing supply disruption.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargo is in the spotlight following strong third-quarter earnings that surpassed analyst expectations on both top and bottom lines, further bolstered by the recent removal of its long-standing regulatory asset cap. While investors are actively debating the bank's growth trajectory and newfound operational freedom, sentiment is being tempered by broader market caution regarding persistent geopolitical risks, trade tensions, and potential loan quality concerns in the wider financial sector.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense social media debate as investors weigh the company's aggressive store expansion and strong brand loyalty against valuation concerns and a high forward P/E ratio. The community is actively tracking upcoming earnings and comparing the stock's growth trajectory to sector stalwarts like Starbucks.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade is trending as investors weigh the significant potential of its Rio Grande LNG expansion against the backdrop of global energy volatility and geopolitical shifts. Community discussion remains polarized, with bullish sentiment driven by major institutional accumulation and long-term infrastructure contracts, while skeptics point to the company's debt-heavy balance sheet and the long lead time before full-scale commercial operations.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is experiencing intense community focus as short interest reaches record highs, fueling speculation of a potential short squeeze amid significant cloud infrastructure and GPU capacity expansion. Investors are heavily debating the stock's long-term valuation in light of strategic advertising and cloud spending commitments from Tether, alongside concerns regarding recent price volatility and the ongoing acquisition of Northern Data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.&nbsp;</li><li>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises.</li><li>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde.</li></ul><p>Wall Street on Wednesday reiterated confidence in Protagonist Therapeutics (PTGX) after John and Johnson received U.S. Food and Drug Administration’s approval for Icotyde for the treatment of moderate-to-severe plaque psoriasis.</p><p>The FDA approved the drug in adults and pediatric patients 12 years of age and older. The approval was based on four late-stage studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients.</p><h2 class="st-heading-2">Protagonist’s Role In Icotyde</h2><p>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.</p><p>FDA approval of Icotyde triggers a $50 million milestone payment to Protagonist, the company said, while adding that it is eligible eligible to receive up to $580 million in potential additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales.</p><h2 class="st-heading-2">Analyst Take</h2><p>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises. Johnson &amp; Johnson is committed to building Icotyde into a blockbuster, which should create "significant value" for Protagonist Therapeutics (PTGX), the analyst told investors in a research note.</p><p>H.C. Wainwright believes Icotyde is positioned to "transform the plaque psoriasis landscape with a differentiated label that highlights its superior efficacy and safety profile." The firm reiterated a ‘Buy’ rating on Protagonist with a $117 price target.</p><p>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde. The approval transitions Protagonist into a company with royalty-bearing commercial exposure, while retaining upside from lifecycle expansion and the broader pipeline, the firm said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PTGX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/PTGX">PTGX stock</a> has gained 78% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-chair-powell-says-iran-war-will-spike-inflation-in-the-near-term-but-too-soon-to-assess-impact/cZ37Nb9RIW5">Fed Chair Powell Says Iran War Will Spike Inflation In The Near Term, But Too Soon To Assess Impact</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 

Equity

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 


Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - What's Next...

Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC

HighVista Strategies LLC increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 110.3% in the third quarter, according to its most recent 13F filing with the...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are covering the stock, MarketBeat Ratings reports...

Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC

Boxer Capital Management LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 83.3% during the 3rd quarter, according to the company in its most recent filing with...

Commodore Capital LP Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX

Commodore Capital LP lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 4.7% in the third quarter, according to the company in its most recent Form 13F...

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC

Mangrove Partners IM LLC lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 21.0% during the third quarter, according to its most recent disclosure with...

Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 18. (View Earnings Report at...

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High - Should You Buy?

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why...

Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX

Intech Investment Management LLC cut its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 36.3% during the third quarter, according to its most recent 13F filing with the...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Current Price	$97.09
Prev Close	$97.23
Open	$97.04
Dividend Yield	0.00%
50-Day Moving Average	$86.13
Beta	0.57
Avg. Volume	603,765.99
PE Ratio	-47.60

52-Week High	$99.31
52-Week Low	$39.60
Market Capitalization	$6.2B
EPS (Annual)	-$2.05
Price to Book	9.90
Revenue Per Employee	$348,606.06

PTGX
Protagonist Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTGX News

PTGXProtagonist Therapeutics Inc